BMS-986094, a 2'-C-methylguanosine prodrug that was in development for treatment of chronic hepatitis C infection was withdrawn from Phase 2 clinical trials because of unexpected cardiac and renal adverse events. Investigative nonclinical studies were conducted to extend the understanding of these findings using more comprehensive endpoints. BMS-986094 was given orally to female CD-1 mice (25 and 150 mg/kg/d) for 2 weeks (53/group) and to cynomolgus monkeys (15 and 30 mg/kg/d) for up to 6 weeks (2-3/sex/group for cardiovascular safety, and 5/sex/group for toxicology). Endpoints included toxicokinetics; echocardiography, telemetric hemodynamics and electrocardiography, and tissue injury biomarkers (monkey); and light and ultrastructural pathology of heart, kidney, and skeletal muscle (mouse/monkey). Dose-related and time-dependent findings included: severe toxicity in mice at 150 mg/kg/d and monkeys at 30 mg/kg/d; decreased left ventricular (LV) ejection fraction, fractional shortening, stroke volume, and dP/dt; LV dilatation, increased QTc interval, and T-wave flattening/inversion (monkeys at ! 15 mg/kg/d); cardiomyocyte degeneration (mice at 150 mg/kg/d and monkeys at ! 15 mg/kg/d) with myofilament lysis/myofbril disassembly; time-dependent proteinuria and increased urine b-2 microglobulin, calbindin, clusterin; kidney pallor macroscopically; and tubular dilatation (monkeys); tubular regeneration (mice 150 mg/kg/d); and acute proximal tubule degeneration ultrastructurally (mice/monkeys); and skeletal muscle degeneration with increased urine myoglobin and serum sTnI. These studies identified changes not described previously in studies of BMS-986094 including premonitory cardiovascular functional changes as well as additional biomarkers for muscle and renal toxicities. Although the mechanism of potential toxicities observed in BMS-986094 studies was not established, there was no evidence for direct mitochondrial toxicity.
antivirals [DAAs] ) were approved in the United States and European Union for the treatment of chronic hepatitis C (Poordad et al., 2011; Sherman et al., 2010) . However, side effects and marginal effectiveness drove research into new HCV treatments (McGuigan et al., 2011) . More recently, inhibitors targeting NS3/4 protease (simeprevir), NS5a (daclatasvir), and NS5b RNAdependent RNA polymerase (RdRp) (sofosbuvir) were approved for use Lok et al., 2012) .
Developing new DAAs for the treatment of HCV with improved efficacy and safety relative to existing DAAs in a broad population of HCV-infected patients was a high priority for Bristol-Myers Squibb (BMS). Accordingly, BMS introduced a novel nucleotide polymerase (NS5B) inhibitor, BMS-986094, into Phase 2 clinical development. BMS-986094 is a 2 0 -C-methylguanosine RdRp prodrug with pivalate and 1-naphthol moieties. Nonclinical data indicated that BMS-986094 was potent against genotypes 1-4 and demonstrated additive or synergistic effects with other HCV targeting inhibitors. In addition, BMS-986094, similar to other RdRp inhibitors, was expected to have a high barrier to viral resistance (Najera, 2013; Sarrazin et al., 2012) . Dose-limiting adverse side effects from antiviral therapies have been a leading cause of drug discontinuation in clinical trials. With early antiviral therapies (interferon a2b or PEGylated interferon a2a in combination with Ribovarin [RBV] ), side effects included fatigue, flu-like symptoms, anemia, neutropenia, thrombocytopenia, and neuropsychiatric symptoms, predominantly depression (Bobeck et al., 2010; Feld, 2014; Fried, 2002; McHutchison et al., 2002) . Additionally, some DAA inhibitors have been associated with adverse clinical effects including gastrointestinal (GI) toxicity, lymphopenia, anemia, hepatotoxicity, and skin reactions (Feld, 2014; Legrand-Abravanel et al., 2010; Pockros et al., 2008) . Inhibition of mitochondrial DNA polymerase has been implicated in the development of multi-organ toxicities associated with nucleoside/ nucleotide polymerase inhibitors (Koczor and Lewis, 2010; Lewis et al., 2003; McKenzie et al., 1995) .
BMS-986094, either alone or combined with RBV, was well tolerated clinically and exhibited dose-dependent antiviral activity in treatment naive HCV genotype 1-infected patients over 7 days (Rodriguez-Torrez et al) . However, in a Phase 2 clinical study, dosing with BMS-986094 was terminated after a patient experienced rapidly progressive reduced cardiac function (decreased left ventricular [LV] ejection fraction [EF] and electrocardiogram [ECG] changes) and acute renal injury (increased serum creatinine) after 4 weeks of treatment (Ahmad et al., 2015) . Other cases of unexpected cardiac and renal adverse events were later observed.
In prior animal studies with BMS-986094 up to 6 months in duration, multiple target-organ toxicities (skeletal muscle, heart, kidney, GI tract, lymph nodes, and bone marrow) were observed at nontolerated doses, and effects at tolerated doses were largely limited to minimal skeletal muscle degeneration at low multiples of the projected clinical exposure. Since skeletal muscle degeneration for BMS-986094 correlated with increases in standard serum chemistry analytes (eg, transaminases and creatine kinase [CK] ), it was expected that clinical dosing could proceed safely with appropriate monitoring. However, the rapid onset and severity of clinical adverse cardiovascular events without premonitory changes in serum biochemistry parameters were unexpected. Therefore, BMS conducted a series of in vitro and in vivo investigative studies to further characterize the mechanisms of potential toxicity observed in nonclinical and clinical trials of BMS-986094 using innovative, and in some cases newly developed, mechanistic and diagnostic methodologies. The following studies are described herein: 1) 1 to 1.5-month cardiovascular safety study in monkeys including toxicokinetics, clinical pathology with cardiovascular and skeletal-muscle toxicity biomarkers, limited histopathology, serial echocardiography, and serial ECG and LV and arterial hemodynamic evaluations utilizing intrathoracic telemetry; 2) 1-month toxicology study in monkeys including toxicokinetics, clinical pathology with cardiovascular and skeletal-muscle toxicity biomarkers, and light microscopic and ultrastructural pathology; and 3) 2-week toxicology study in mice including toxicokinetics, clinical pathology, and light microscopic and ultrastructural pathology. Animal preparation. For the cardiovascular safety study, nonnaive monkeys were obtained from the telemetry colony and had been free of other drug treatments for at least 1-month prior to the start of the study. Animals in the colony had been instrumented with commercial telemetry implants (TL11M3-D70 PCTP, Data Sciences International, Saint Paul, Minnesota). The transmitter was placed in the abdominal cavity and secured to the abdominal wall. The ECG leads were positioned intra-thoracically with the positive lead positioned directly to the myocardium near the apex of the heart, while the negative lead was secured to the mediastinal reflection at the base of the heart. A pressure transducer was placed in the femoral artery for systemic arterial pressure measurement. A second pressure transducer was placed in the left ventricle for LV pressure measurement. All surgical procedures were performed by BMSs Veterinary Care and Research Support. On each measurement day, heart rate, systemic arterial blood pressures (systolic, diastolic, and mean), LV pressure (systolic, and end diastolic), LV pressure derived dP/dt, ECG parameters (P duration; PR, RR, QRS, and QT intervals; Twave and ST-segment heights), physical activity, and core body temperature were evaluated from all animals for a 1-h period approximately 1-3 h prior to treatment and for at least 22 h following treatment. Data were collected at a 10-s logging rate and filtered to remove electrical or mechanical noise, and compiled into 5-min means across the 22-h test sessions. Raw QT interval data were corrected to a heart rate of 500 beats per minute (QTca) based upon individual animal QT-RR relationships obtained during predose baseline monitoring (Holzgrefe et al., 2007) . Periods for analysis and reporting were selected from the light and dark phases of the diurnal cycle. The same periods were selected across treatment groups and generally were 5-7 h after dose (light phase) and 9-12 and 14-17 h after dose (dark phase). There were no noteworthy differences in response between the light and dark phase periods. Data are presented as change from pretest. For dP/dt outliers, data for the entire test session (excluding periods of animal handling) were used. Excerpts of the ECG tracings from the telemetry data stream during the dark and light phase of the diurnal cycle were examined for abnormalities in rate, rhythm, and waveform morphology. Quantitative changes in telemetry measurements for BMS-986094-treated animals are presented graphically as fold changes from pretest, without correction for concurrent data from the vehicle-treated group.
MATERIAL AND METHODS

Animals
Clinical pathology. Clinical pathology evaluations were performed for all monkeys and 8-10 mice per group. Hematology and coagulation data from monkeys were evaluated for prestudy animal-health screening only and are not reported. Blood samples for serum chemistry evaluations were obtained via cardiac puncture from nonfasted mice just prior to necropsy and from the femoral vein from fasted monkeys. In monkeys, standard serum chemistries and cardiac troponin I (cTnI) were measured once or twice prior to the first dose, weekly during the dosing period, and once weekly during the recovery period. Additionally, serum skeletal muscle troponin (sTnI), standard urinalysis, and a urine kidney injury panel were examined once or twice prior to the first dose, during Weeks 2 and 4, and once during the recovery period. Endpoints evaluated included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase, glucose, urea nitrogen, creatinine, total protein, albumin, cholesterol, triglycerides, total bilirubin, calcium, sodium, potassium, chloride, CK, aldolase, and urine protein, albumin, and creatinine (ADVIA 1800, Siemens Healthcare Diagnostics Inc. Malvern, Pennsylvania); urine aldolase (Roche kit on the ADVIA 1800); urine color, clarity, specific gravity, pH, glucose, ketone, bilirubin, blood, and urobilinogen (Clinitek ATLAS, Siemens Healthcare Diagnostics, Inc.); cTnI (Advia Centaur CP, Siemens Healthcare Diagnostics, Inc.); myoglobin, sTnI (Life Diagnostics Inc West Chester, Pennsylvania); NTproBNP (Wuhan EIAab Science Co., Ltd. Wuhan, China); and a kidney injury panel-urine b2 microglobulin, calbindin 28, cystatin C, clusterin, and neutrophil gelatinase-associated lipocalcin (NGAL) (Rules Based Medicine, Austin, Texas). The latter urine-specific markers of toxicity were not included in the cardiovascular safety study in monkeys.
Anatomic pathology. All monkeys were euthanatized by sedation with ketamine hydrochloride followed by anesthesia with intravenous propofol and subsequent exsanguination. Necropsy included gross examination of heart, kidney, liver, skeletal muscle (psoas, tongue, diaphragm), and sciatic nerve. These tissues were fixed in 10% neutral buffered formalin, processed and embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined by light microscopy. Heart sections were stained with Masson's trichrome for evaluation of fibroplasia/ fibrosis. Oil Red O stains for the detection of neutral lipids were performed on tissue sections of formalin-fixed frozen heart (left and right ventricle and interventricular septum) from control and high-dose animals. Ultrastructural evaluation (transmisson electron microscopy [TEM]) included examination of the heart (left ventricle and papillary muscle), diaphragm, and kidney. Ultrastructural tissue samples from selected monkeys based on light microscopic findings were processed in McDowell-Trump fixative, post-fixed in osmium tetroxide, embedded in epon, sectioned at approximately 1 micron, stained with toluidine blue, and examined by light microscopy to select the appropriate blocks and areas within blocks for final examined by TEM. Selected blocks were ultrathin sectioned, stained with uranyl acetate and lead citrate, and examined using an FEI Tecnai G2 Spirit BioTWIN transmission electron microscope (Hillsboro, Oregon). Images of representative ultrastructural observations were captured by an Advanced Microscopy Techniques Corp. (Woburn, Massachusetts) camera system. Captured images were archived in the Scientific Image Management System Database, BioImagene, v 2.1.5 (Sunnyvale, California).
Mice were euthanatized by isoflurane and subsequent exsanguination. Necropsy included gross examination of heart, kidney, and skeletal muscle (quadriceps femoris). These tissues were fixed in 10% neutral buffered formalin, processed and embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined by light microscopy. Kidneys also were stained with a McManus periodic acid-Schiff stain to evaluate the proximal tubule brush border. Additionally, phosphotungstic acid-hematoxylin staining was performed on hearts to better assess cardiomyocyte fibers. Ultrastructural evaluation of heart, kidney, and skeletal muscle was carried out as described for monkey tissues.
Analysis of results. Mean body weight and quantitative clinical pathology data from the drug-treated groups were compared with the corresponding control groups by Dunnett's test (for parameters with n ! 3). For telemetry and echocardiography data, mean change from pretest values for the vehicle and drugtreated groups were compared using a 1-way analysis of variance (ANOVA) model. Comparisons between the vehicle and drug-treated group means were performed in the context of the ANOVA model. For telemetry data, analyses were performed separately for the day time and night time periods during each test session. Two-sided t-tests were computed at the 5% significance level. Statistically significant differences of P .05 were reported.
RESULTS
Toxicokinetics BMS-986094 is a prodrug ultimately converted to the active compound, 2 0 -C-methyl guanosine triphosphate (INX-09114).
Major metabolites in this pathway include the prodrug less naphthol (INX-09054), the initial nucleoside (INX-08032), and the O-methyl nucleoside (INX-08114). The predominant measurable analyte in plasma was INX-08032 and, as such, it was used as the primary measure of exposure. In Week 5 of the monkey toxicology study, BMS-986094 was detectable in plasma only at early timepoints ( 4 h) at 30 mg/kg/d, with concentrations in most samples at 15 and 30 mg/kg/d less than the lower limit of quantification (LLOQ 1 ng/ml) ( Table S1 ). The reason for the difference is unclear since the animal source and treatment regimen were identical, and the age and weight of the animals was similar between the studies. The same procedures were used for the dose preparation, though drug content in the formulations was not verified. The toxicokinetic summary for the monkey toxicology study is presented in Table 1 . In the mouse 2-week study, INX-08032 AUC values increased in an approximately dose-proportional manner from 25 to 150 mg/kg/d of BMS-986094 (1460 and 11 500 ng•h/ml, respectively).
Clinical Assessment and Mortality
Adverse clinical findings were largely limited to 2 monkeys in the cardiovascular safety study and 3 monkeys in the toxicology study at 30 mg/kg/d that were euthanatized in moribund condition on Day 32 (cardiovascular study) and Days 27, 29, and 33 (toxicology study). These signs included reduced food consumption starting in Week 4 and decreased activity, pallor, dehydration, hypothermia, tachycardia and decreased respiratory rate during Week 5. There were no clear effects on body weight.
Hemodynamic data in the 2 decedent cardiovascular safety study monkeys indicated substantial decrements in LV function during the week prior to death. Echocardiogram findings on Day 32 included decreased LV EF (0.17Â and 0.46Â), %FS (0.13Â and 0.38Â), and SV (0.37Â and 0.76Â). Absolute EFs for these animals were 12 and 33%, respectively. Cardiac contractility measured telemetrically as dP/dt was decreased initially on Day 9, with maximum decreases occurring on Day 26 (0.53Â and 0.45Â), the final session prior to euthanasia. Arterial systolic blood pressure also was decreased (0.9Â) for these animals in the week prior to euthanasia. Gross and microscopic findings suggestive of congestive heart failure (CHF) included swollen and/or mottled lungs with a microscopic correlate of pulmonary edema and congestion, a thin-walled left ventricle in the heart, and pleural and/or peritoneal fluid. Additional findings in these animals that likely were consequences of reduced cardiac output included mild proximal tubular dilatation of the kidneys, and centrilobular hepatocellular necrosis and dilated lymphatic vessels in the liver. In mice, BMS-986094 was well tolerated at 25 mg/kg/d. At 150 mg/kg/d, mortality or early euthanasia due to poor clinical condition (12 mice) occurred during the first 2 weeks of treatment. Clinical observations included eyelids partially closed, hunched posture, labored respiration, unkempt appearance, decreased feeding behavior, and mild to moderate dehydration. decreases in T-wave amplitude were detected for the 2 decedent animals and 1 surviving animal. Decreased T-wave amplitude progressed to flat T waves and T-wave coving ( Figure 4B ). ST depression was also noted. Similar ECG changes were noted in the monkey toxicology study, in which reversible, timedependent ECG changes at 15 and 30 mg/kg/d were noted as early as 2 weeks after initiation of the dosing (Supplementary  Table S2 ). Finally, data suggesting increases in PR interval were observed for the 2 decedents in the cardiovascular safety pharmacology study, with maximum increases on Days 12 and 16 ( 1.3Â) (data not shown).
Cardiac Function
Clinical and Anatomic Pathology in Monkeys
Heart. Microscopic findings in the heart from monkeys administered BMS-986094 were predominately observed in the left ventricle and included minimal to mild degeneration of cardiomyocytes at 15 and 30 mg/kg/d and minimal fibrosis at 30 mg/kg/d (Table 3, Figure 5 ) . The degenerative cardiomyocytes occasionally contained cytoplasmic vacuoles that correlated ultrastructurally to disassembly of myofibrils and lysis of myofilaments ( Figure 6 ). Administration of BMS-986094 did not alter mitochondrial morphology. In the toxicology study, animals at 30 mg/kg/d with findings of degenerative cardiomyocytes also demonstrated increases in serum cTnI (5.00-20.75Â relative to pretest) that were first identified during Week 3 (Table 4 ). In the cardiovascular safety study, cTnI also was minimally increased for the 2 decedent animals at 30 mg/kg/d (4.7Â and 7.7Â) on study Day 18, and 2 animals at 15 mg/kg/d (2.3Â and 2.6Â) on study Days 4 or 18 with evidence of cardiac adverse findings and CHF (Table 5) . However, changes in cTnI were not observed consistently for animals with myocardial degeneration, and increased cTnI was observed for 1 surviving animal at 30 mg/kg/ d (28Â) without myocardial lesions.
Kidney. BMS-986094 administration was associated with doseand time-dependent renal changes, as indicated by both clinical chemistry and pathologic evaluations. Increases in serum creatinine (1.22-1.85Â vs pretest values) were generally observed at 15 and 30 mg/kg/d starting in Week 1 and continuing throughout the dosing period (Table 4 ). In addition, significant increases in urine total protein output (1.70-7.94Â), urine protein to creatinine ratio (1.86-15.86Â), and urine microalbumin output (2.22-19.69Â) were noted at 15 and 30 mg/kg/d (Table 4 ) starting in Week 2. Similar changes in urine total protein, urine albumin and serum creatinine were observed in the cardiovascular safety study in monkeys (Table 5 ). In the monkey toxicology study, increases in urine renal injury markers such as b2 microglobulin (4.4-60Â), calbindin (1.91-7.75Â), and clusterin (1.75-32.4Â) were observed starting in Week 2 ( perfusion. While there were no corresponding BMS-986094-related light microscopic correlates, transmission electron microscopy at 30 mg/kg/d revealed acute degenerative changes in renal proximal tubular epithelial cells characterized by rarefaction of the cytoplasm, dilatation of endoplasmic reticulum, and lack of distinctive infoldings of the basal plasma membrane along the basement membrane (Figure 7 ). Mitochondria were morphologically normal. There were no BMS-986094-associated increases in urinary renal injury biomarkers nor any macroscopic or microscopic changes in kidneys from monkeys following the 6-week recovery period (data not shown).
Skeletal muscle (psoas, tongue, diaphragm). There were no BMS-986094-associated changes observed in the diaphragm or tongue (data not shown). BMS-986094-associated findings in the skeletal muscle were limited to reversible, minimal to mild degeneration/regeneration of myocytes in the psoas muscle at 30 mg/kg/d that generally correlated with increases in urinary myoglobin output (1.68-106Â relative to pretest) (Tables 3 and 4; Figure 8 ). The increases in urinary myoglobin output were first identified during Week 2 and were generally present throughout the dosing period. In addition, while microscopic findings in skeletal muscle were only observed in the 30-mg/kg/d group, increases in urine myoglobin output were also observed in females at 15 mg/kg/d. However, there were no increases in other routine serum markers of muscular injury (AST, CK, aldolase, or sTnI) at any dose tested in the toxicology study in monkeys (data not shown). In the cardiovascular safety study, changes consistent with skeletal muscle injury included increased urine myoglobin in 1 monkey at 15 mg/kg/d (15.3Â) and all monkeys at 30 mg/kg/d (3.0-114Â) and increased serum sTnI in 3 of 5 monkeys at 15 and 30 mg/kg/d (2.4-14.2Â and 2.0-9.3Â, respectively), (Table 5 ). The serum sTnI and/or the urine myoglobin changes correlated with the skeletal muscle degeneration noted in the psoas muscle of the 2 early decedents.
Clinical and Anatomic Pathology in Mice
There were no BMS-986094-associated microscopic findings at 25 mg/kg/d. Microscopic findings in BMS-986094-treated mice at 150 mg/kg/d included minimal to mild degeneration of cardiomyocytes in the heart and minimal to mild tubular regeneration in the kidneys (bilateral) (Figure 9 ; Supplemental Table S3 ). Cardiomyocyte degeneration was characterized light microscopically by the presence of clear cytoplasmic vacuoles that were most prominent in the left ventricle. Ultrastructurally, cardiomyocyte degenerative changes were characterized by discretely localized loss of myofilaments with accumulation of finely granular material (Figure 10 ). Mitochondria in the degenerate cardiomyocytes were morphologically normal. In the kidneys, tubular regeneration was primarily limited to the proximal tubules and was characterized light microscopically as increased cytoplasmic basophilia and nuclear crowding. Ultrastructurally, several convoluted tubular epithelial cells exhibited acute degenerative changes characterized by diffuse cytoplasmic rarefaction ( Figure 11A ). Also observed within convoluted tubular epithelium were widely scattered condensed and fragmented necrotic or apoptotic cells ( Figure 11B ). Photomicrographs from control mice are presented in Supplemental Figure S2 and S3. BMS-986094-associated serum chemistry changes at 25 and 150 mg/kg/d included to minimal increases in serum calcium and phosphorus. Additional changes at 150 mg/kg/d were increases in serum AST (4.21Â) and ALT (7.27Â) activities and total cholesterol (1.44Â), and decreases in triglycerides (0.18Â). The increases in serum transaminases may have been due to liver toxicity, although the cardiomyocyte degeneration in the heart may have contributed to these changes. No confirmatory liver histology was performed in this study, and there were no drug-related microscopic findings in skeletal muscle.
DISCUSSION
In prior animal studies with BMS-986094 up to 6 months in duration, multiple target-organ toxicities (skeletal muscle, heart, kidney, GI tract, lymph nodes, and bone marrow) were observed at nontolerated doses, and effects at tolerated doses were largely limited to minimal skeletal muscle degeneration at low multiples of the projected clinical exposure. Since skeletal muscle degeneration for BMS-986094 correlated with increases in standard serum chemistry analytes (eg, transaminases and CK), it was expected that clinical dosing could proceed safely with appropriate monitoring. However, the rapid onset and severity of clinical adverse cardiovascular events without premonitory changes in serum biochemistry parameters were unexpected. The nonclinical studies reported here were designed to explore the mechanism(s) for BMS-986094-associated toxicities and identify potential biomarkers using more comprehensive and sophisticated endpoints. Following is a discussion of some key findings in mice and monkeys with relevant correlations to observations in humans.
Pronounced clinical toxicity resulting in euthanasia that was attributed to BMS-986094-associated myocardial toxicity occurred late in the 1-month dosing period or early in the recovery period in 5 monkeys administered 30 mg/kg/d of BMS-986094. Two of the decedents had hemodynamic and anatomic pathology changes consistent with CHF.
BMS-986094-associated cardiac effects in monkeys were dose and time dependent. Cardiovascular changes at 15 and 30 mg/kg/d included reduced T-wave amplitude beginning in Week 1; QTc prolongation, T-wave inversion, and decreased LV contractility (dP/dt) beginning in Week 3; and ventricular dilatation beginning in Week 4. Additional observations at 30 mg/kg/d included abrupt deceases in LV EF and ST segment depression in Weeks 4 and 5, and decreased LV SV in Weeks 4 through 9. Several of these observations were consistent with those identified in some humans (ie, decrease in LV EF after several weeks on drug, loss of T wave and T-wave inversion, and ST segment depression) (Ahmad et al., 2015) . Nonclinical QTc prolongation was a new observation. There were no effect on hERG currents for BMS-986094 or its metabolites in standard preparations of HEK-293 cells stably expressing the cloned hERG potassium channel a subunit, and it is unlikely that the QTc increases were a result of a direct interaction with hERG channels, nor were there electrolyte imbalances in monkeys, which, if present, could cause secondary changes in QTc. However, inhibition of hERG currents has been demonstrated for BMS-986234 in human cardiomyocytes, which may have contributed to the effects observed (Anwar-Mohamed et al., 2014) . It is also possible that the changes in QTc reflect cardiac remodeling since remodeling and increased QT interval have been demonstrated in nonclinical models of heart failure and decreased ventricular function (Kharin et al., 2012; Rosenberger et al., 2011; Shi et al., 2013) , and the onset of QT-interval changes in the cardiovascular safety study coincided with the onset of decreased ventricular function. All BMS-986094-associated cardiac changes in monkeys were partially to fully reversible, with exception of LV dilatation, which was not associated with functional deficits. Microscopically, BMS-986094-associated myocardial degeneration occurred in mice at 150 mg/kg/d and in monkeys at 15 and 30 mg/kg/d with myocardial interstitial fibrosis only at the high dose of 30 mg/kg/d. These BMS-986094-associated light microscopic findings in the myocardium were consistent with those observed in a prior 2-week study in mice at 200 mg/kg/d and at comparable systemic exposures in prior monkey studies ! 2 weeks in duration (data not shown). In the cardiovascular safety study in monkeys, a definitive assessment of BMS-986094-associated cardiac changes could not be made as similar microscopic lesions secondary to the implantation of cardiac telemetry leads were observed in control and treated monkeys. Ultrastructural examination of the heart in monkeys and mice demonstrated lysis of myofilaments and disassembly of myofibrils that likely correlated with cardiomyocyte vacuolation observed light microscopically in both species with dilated sarcoplasmic reticulum and formation of myelin figures in monkeys. Notably, the number and morphology of mitochondria in the myocardium of BMS-986094-treated mice and monkeys were comparable to concurrent controls. These data suggest that the decline in cardiac function may be associated with cardiac architectural damage impacting the contractile capacity of the cardiomyocytes and that BMS-986094 is not a direct mitochondrial toxicant. Consistent with the absence of direct mitochondrial effects, there were no decreases in mitochondrial respiration or in the concentrations of high energy substrates (ATP, GTP) in the heart or kidneys of monkeys in these studies Scarpa, 1979) . Although drug-induced cardiotoxicity without apparent effects on mitochondria has been reported with other xenobiotics (Adoa et al., 2013) , the absence of any effects on mitochondria with BMS-986094 was somewhat unexpected given the observed cardiomyocyte cytoskeletal changes and the intimate association between the cytoskeleton and mitochondria in cardiac and skeletal muscles. Transcriptional profiling demonstrated changes in the hearts of BMS-986094-treated mice and monkeys that may have been associated with degenerative changes and reductions in cardiac function, and correlated with the cytoskeletal and sarcomere changes observed ultrastructurally (Brown et al., 2006; Noma et al., 2006) . These included downregulation of genes associated with GTPase activity (Rho, Rab, Rac, and Ras), myofiber cytoskeleton, and calcium signaling. Therefore, it is plausible that altered/perturbed Rho regulation and calcium signaling resulted in the breakdown and disarray of myofibers and sarcomeres in muscle cells because of their key roles in cytoskeletal organization (Amano et al., 1996; Bowman et al., 2008; Hoshijima et al., 1998; Sit and Manser, 2011; Yano et al., 2005) but this hypothesis requires further investigation.
Correlative, but generally minimal increases in serum levels of cTnI were observed 2 weeks prior to euthanasia of decedent monkeys with myocardial degeneration. However, elevated cTnI was not observed consistently for other animals with myocardial degeneration. The inconsistent correlation of serum cTnI increases and the myocardial degeneration were attributed to the limited time points taken for this biomarker and its short half-life in serum (Dunn et al., 2011; Wells and Sleeper, 2008) .
BMS-986094 treatment in monkeys was associated with dose-and time-dependent increases in serum creatinine beginning in Week 1 and increases in urine total protein, albumin, and urine renal injury biomarkers (b2 microglobulin, calbindin, and clusterin) beginning in Week 2. Increases in serum creatinine with no effect on urine protein were observed in prior studies in monkeys with BMS-986094 (data not shown). BMS-986094-associated morphologic changes in the kidneys in the present studies included pale discoloration macroscopically with no light microscopic correlate in several monkeys at 30 mg/kg/d that suggested reduced vascular perfusion, proximal tubular dilatation in 1 monkey at 30 mg/kg/d that was attributed to hemodynamic changes associated with CHF, and tubular regeneration in mice at 150 mg/kg/d and acute degenerative changes in proximal tubular epithelial cells identified ultrastructurally in mice at 150 mg/kg/d and monkeys at 30 mg/kg/d. Though potentially impacted by reduced vascular perfusion, these changes along with the proteinuria and increases in renal injury biomarkers suggested potential direct effects of BMS-986094 on the kidneys with associated proximal tubular injury. Moreover, the renal morphologic changes in these studies were generally consistent with those identified in prior studies that included tubular regeneration in mice and proximal tubular degeneration/necrosis in some early decedent monkeys (data not shown). As toxicogenomics analysis of the kidneys from BMS-986094-treated mice and monkeys demonstrated significant downregulation of genes for megalin and cubulin , it is also plausible that reductions in cubulin and megalin proteins in the proximal tubules that have critical roles in the endocytosis of albumin as well as vitamins, lipids, and hormones (Moestrup and Verroust, 2001; Verroust et al., 2002 ) also contributed to the proteinuria and increases in urine biomarkers. The BMS-986094-associated proteinuria and increased renal injury biomarkers were fully reversible.
BMS-986094-associated observations related to skeletal muscle injury in monkeys included degeneration/regeneration of myofibers in psoas muscle at 30 mg/kg/d and increases in serum sTnI and urine output of myoglobin at 15 and 30 mg/kg/ d. Myoglobin is an oxygen-binding protein specific for cardiac and skeletal muscle that is released following muscle injury and excreted in urine. Urinary myoglobin appeared to be a reliable and sensitive biomarker for cardiac and skeletal muscle injury in this study, particularly given the absence of changes in other standard serum markers of skeletal muscle injury (ie, transaminases, CK) in these studies. BMS-986094-associated skeletal muscle adverse findings accompanied by increases in serum transaminases and CK was observed in prior studies in monkeys of 3 and 6 months duration (data not shown). The increases in serum transaminase and CK in these subchronic/ chronic toxicity studies observed in animals administered BMS-986094 suggests that the muscle findings were more extensive with longer dosing. As with the heart, the toxicogenomic findings in skeletal muscle also suggested that changes in calcium signaling and Rho GTPase activities may have roles in the Data from a parallel study conducted in monkeys administered BMS-986094 for 3 weeks at 15 and 30 mg/kg/d indicated relatively high concentrations and slow clearance of the active metabolite (INX-09114) in the heart and kidney (Trouba et al., 2014) . Considering that the heart and kidneys are major target organs of potential toxicity for BMS-986094, it is possible that persistent high concentrations of INX-09114 in these two tissues were involved in the adverse cardiac and renal findings observed.
The comprehensive measures included in these studies extended our understanding of the nonclinical findings in studies of BMS-986094. Dose-related cardiovascular changes were observed coincident with (decreased LV EF) and prior to the onset of overt toxicity (LV dP/dt, cTnI, QTc prolongation, T-wave alterations). Additionally, biomarkers were identified for skeletal (sTnI and urine myoglobin) and renal (urine protein output, b-2 microglobulin, calbindin, and clusterin) changes. While the mechanisms of findings in studies of BMS-986094 were not established, the changes associated with BMS-986094 were inconsistent with a direct effect on mitochondria. Finally, there was an apparent correlation of persistent high tissue nucleoside triphosphate levels to cardiac and renal toxicity.
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